Larimar Therapeutics rises after FDA partially lifts clinical hold on rare disease drug

Larimar Therapeutics

14/09/2022 16:07

** Shares of Larimar Therapeutics Inc  LRMR.O  up ~2% at
$3.20
    ** Company says U.S. FDA lifts full clinical hold on its
experimental CTI-1601 program and imposes a partial hold
 urn:newsml:reuters.com:*:nGNX38Tdx
    ** LRMR says health regulator has allowed it to begin dosing
in the 25 microgram cohort of its mid-stage study for CTI-1601
    ** Company expects to begin mid-stage trial in Q4 2022, with
top-line data expected in H2 2023
    ** Larimar to test CTI-1601 as a potential treatment of
Friedreich's ataxia, a rare inherited disease causing
progressive nervous system damage and movement problems
    ** FDA put LRMR's early-stage trial for CTI-1601 on full
clinical hold last year, following notification of mortalities
that occurred at highest dose levels in a non-human primate
study (https://bit.ly/3eNuLs2)
    ** As of last close, company's shares down ~71% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788))